In the CGGA cohort of patients, for instance, we observed a 5-year OS of 18% versus 68% for primary glioma patients with higher ABCC1 expression versus lower ABBC1 expression, respectively (p < 0.0001) (Fig. 6E). This evidence concerns the gene ABCC1 and central nervous system cancer.